Plus   Neg

MacroGenics Shares Surge On Positive Margetuximab Data

MacroGenics, Inc. (MGNX) announced positive results from SOPHIA, the company's Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half of 2019.

In Wednesday pre-market trade, MGNX is trading at $23.52, up $12.41 or 111.70 percent.

Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company's proprietary Fc Optimization technology platform. The SOPHIA clinical trial met the primary endpoint of prolongation of progression-free survival or PFS in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033).

For comments and feedback contact: editorial@rttnews.com

Follow RTT